Sreekanth K. Chaguturu - Aug 31, 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Chief Medical Officer
Signature
/s/ Sreekanth K. Chaguturu
Stock symbol
CVS
Transactions as of
Aug 31, 2022
Transactions value $
$0
Form type
4
Date filed
9/2/2022, 04:50 PM
Previous filing
Jun 30, 2022
Next filing
Dec 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock (RSU) Award $0 +12.7K $0.00 12.7K Aug 31, 2022 Direct F1
holding CVS Common Stock (RSU) 996 Aug 31, 2022 Direct F2
holding CVS Common Stock (RSU) 354 Aug 31, 2022 Direct F3
holding CVS Common Stock (RSU) 2.15K Aug 31, 2022 Direct F4
holding CVS Common Stock (RSU) 1.26K Aug 31, 2022 Direct F5
holding CVS Common Stock (RSU) 2.09K Aug 31, 2022 Direct F6
holding CVS Common Stock (RSU) 2.78K Aug 31, 2022 Direct F7
holding CVS Common Stock (RSU) 6.18K Aug 31, 2022 Direct F8
holding CVS Common Stock 2.34K Aug 31, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 5.95K Aug 31, 2022 Common Stock 5.95K $75.27 Direct F9
holding CVS Stock Option 9.58K Aug 31, 2022 Common Stock 9.58K $58.34 Direct F10
holding CVS Stock Option 9.5K Aug 31, 2022 Common Stock 9.5K $74.30 Direct F11
holding CVS Stock Option 13K Aug 31, 2022 Common Stock 13K $101.09 Direct F12

Explanation of Responses:

Id Content
F1 Consists of RSUs awarded pursuant to the Issuer's 2017 Stock Incentive Plan. Restrictions lapse on the third anniversary of the grant date.
F2 Consists of Restricted Stock Units (RSUs) awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse on the third anniversary of the grant date.
F3 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse on 2/28/2023.
F4 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F5 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on the remaining RSUs lapse in two equal installments beginning 4/1/2023.
F6 Consists of remaining RSUs awarded pursuant to the Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in two equal installments beginning 2/26/2023.
F7 Consists of RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions on remaining RSUs lapse in three equal installments beginning 4/1/2023.
F8 Consists of remaining RSUs awarded pursuant to the Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal installments beginning 4/1/2023.
F9 Option became exercisable in four equal annual installments, commencing 11/29/2020.
F10 Option became exercisable in four equal annual installments, commencing 4/1/2021.
F11 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F12 Option becomes exercisable in four equal annual installments, commencing 4/1/2023.